Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 12/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12403858 | 0.79 | HTT (0.46) | — | |
| SCHEMBL12883442 | 0.78 | RAPGEF4 (0.39) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL13119527 | 0.77 | MAP2K1 (0.42) | MAP2K1MAP2K2FLT1IDO1 | |
| SCHEMBL12883439 | 0.76 | LMNA (0.42) | MAP2K1 | |
| SCHEMBL239073 | 0.76 | IDO1 (0.35) | IDO1 | |
| SCHEMBL12883490 | 0.76 | KMT2A (0.44) | FLT1 | |
| SCHEMBL19194233 | 0.76 | GAA (0.43) | IDO1 | |
| SCHEMBL24463592 | 0.76 | IDO1 (0.35) | IDO1 | |
| SCHEMBL12403870 | 0.73 | RAB9A (0.42) | — | |
| SCHEMBL12367895 | 0.72 | MAP2K1 (0.46) | MAP2K1MAP2K2FLT1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | PSMB1, UBQLN1, PSMB5 | MAP2K1 4289/4885MAP2K2 4007/4885FLT1 4673/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | MAP2K1 4594/4885MAP2K2 4487/4885FLT1 3726/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | MAP2K1 4636/4885MAP2K2 4481/4885FLT1 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.